Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

9    Amgen    $13.1B     up 3.1%
Global revenue: $15.6B (15th); up 3.3%

R&D spend: $3.2B (14th), up 10.3%; 20.5% of rev.

Top brands: Enbrel ($3.5B), Neulasta ($3.0B), Epogen ($2.0B), Sensipar ($518M), Xgeva ($343M)

Planned launches: AMG386 (onc.); ganitumab (onc.)

Promotional spend: $346M (15th); 2.6% of rev.

Patent expirations: Neupogen (2013), Neulasta (2015), Epogen (2015), Sensipar (2015)

Amgen has enjoyed a stable of top-earning biologic products. Over the next several years, many of the patents on these products will expire, and the company expects to face competition, including from biosimilars. Teva has already filed a BLA for a Neupogen-like biosimilar. Amgen's ESA drugs Aranesp and Epogen have also been buffeted by new CMS bundling rules and by warnings on their labels. Launches of denosumab drugs Prolia and Xgeva haven't met projections. Luckily for Amgen, top seller Enbrel shouldn't see biosimilar competition for some time—Amgen and ex-US marketing partner Pfizer just locked up protection for another 17 years. Moreover, the Enbrel co-promote expires in late 2013, after which Amgen will pocket overseas revenues for the biologic, as well.

Back to first page

Page 9 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...